FDA-cleared profile

Rayvolve

AZmed SAS · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: Assists radiologists and emergency physicians in detecting fractures on DICOM musculoskeletal radiographs for adults and children aged 2 years or older, limited to the FDA-listed anatomic areas and standard views (ankle, clavicle, elbow, forearm, hip, humerus, knee, pelvis, shoulder, tibia/fibula, wrist, hand, and foot); it is an aided-diagnosis device and does not operate autonomously.

Clinical role
Detection, localization, or diagnostic support; aided diagnosis and not autonomous operation.
Images and patients
X-ray/Radiography · MSK
Key limitation
Keep in mind: Rayvolve does not replace medical doctors. Performance figures are endpoint- and population-specific; K240845 reports no new clinical study and references the predicate Rayvolve clinical-reader study. Local DICOM/PACS compatibility, commercial security, price, and service terms require qualification.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Assists radiologists and emergency physicians in detecting fractures on DICOM musculoskeletal radiographs for adults and children aged 2 years or older, limited to the FDA-listed anatomic areas and standard views (ankle, clavicle, elbow, forearm, hip, humerus, knee, pelvis, shoulder, tibia/fibula, wrist, hand, and foot); it is an aided-diagnosis device and does not operate autonomously.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: MSK Input: DICOM radiographs from a DICOM Node or PACS, limited to the FDA-listed musculoskeletal study types and standard views: ankle, clavicle, elbow, forearm, hip, humerus, knee, pelvis, shoulder, tibia/fibula, wrist, hand, and foot.
  • Who uses it?Intended users: Radiologists and emergency physicians.
  • What does the software produce?Output: Rayvolve outputs a prediction of potential fracture presence or absence and a processed image with bounding-box annotations localizing detected fractures; the initial image appears first and the processed image follows in the DICOM workflow, with annotations toggleable in the PACS/viewer.
  • What is its most important limitation?Key limitation: Rayvolve does not replace medical doctors. Performance figures are endpoint- and population-specific; K240845 reports no new clinical study and references the predicate Rayvolve clinical-reader study. Local DICOM/PACS compatibility, commercial security, price, and service terms require qualification.

Clinical takeaway. Clinical role: Assists radiologists and emergency physicians in detecting fractures on DICOM musculoskeletal radiographs for adults and children aged 2 years or older, limited to the FDA-listed anatomic areas and standard views (ankle, clavicle, elbow, forearm, hip, humerus, knee, pelvis, shoulder, tibia/fibula, wrist, hand, and foot); it is an aided-diagnosis device and does not operate autonomously.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA submission reports standalone pediatric performance on 3,016 radiographs across all indicated study types and views: sensitivity 0.9611, specificity 0.8597, and ROC-AUC 0.9399. The submission states that no new clinical study was conducted for K240845 and references the predicate Rayvolve clinical reader study separately.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Assists radiologists and emergency physicians in detecting fractures on DICOM musculoskeletal radiographs for adults and children aged 2 years or older, limited to the FDA-listed anatomic areas and standard views (ankle, clavicle, elbow, forearm, hip, humerus, knee, pelvis, shoulder, tibia/fibula, wrist, hand, and foot); it is an aided-diagnosis device and does not operate autonomously.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Detection, localization, or diagnostic support; aided diagnosis and not autonomous operation.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
DICOM radiographs from a DICOM Node or PACS, limited to the FDA-listed musculoskeletal study types and standard views: ankle, clavicle, elbow, forearm, hip, humerus, knee, pelvis, shoulder, tibia/fibula, wrist, hand, and foot.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
Rayvolve outputs a prediction of potential fracture presence or absence and a processed image with bounding-box annotations localizing detected fractures; the initial image appears first and the processed image follows in the DICOM workflow, with annotations toggleable in the PACS/viewer.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Radiology and emergency-care review of adult and pediatric patients aged 2 years or older.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Radiologists and emergency physicians.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
Rayvolve does not replace medical doctors. Performance figures are endpoint- and population-specific; K240845 reports no new clinical study and references the predicate Rayvolve clinical-reader study. Local DICOM/PACS compatibility, commercial security, price, and service terms require qualification.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
The exact FDA submission reports standalone pediatric performance on 3,016 radiographs across all indicated study types and views: sensitivity 0.9611, specificity 0.8597, and ROC-AUC 0.9399. The submission states that no new clinical study was conducted for K240845 and references the predicate Rayvolve clinical reader study separately.
  • Exact FDA submission
  • Checked 2026-09-07

The 3,016-case results are standalone pediatric testing; do not merge them with predicate adult clinical-reader results.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA submission reports standalone pediatric performance on 3,016 radiographs across all indicated study types and views: sensitivity 0.9611, specificity 0.8597, and ROC-AUC 0.9399. The submission states that no new clinical study was conducted for K240845 and references the predicate Rayvolve clinical reader study separately.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07

The 3,016-case results are standalone pediatric testing; do not merge them with predicate adult clinical-reader results.

Reported sensitivity
96.11% (95% Wilson CI 94.80%-97.10%) in the exact FDA standalone pediatric dataset.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07

Endpoint is image-level standalone sensitivity for the pediatric dataset; the structured metric records the paired specificity and AUC separately.

Reported specificity
85.97% (95% Wilson CI 84.34%-87.45%) in the exact FDA standalone pediatric dataset.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07

Endpoint is image-level standalone specificity for the pediatric dataset.

Standalone sensitivity

0.9611 proportion

  • EndpointImage-level fracture detection
  • PopulationPediatric patients aged 2 years or older; all indicated study types and views, 3,016 radiographs
  • Tested versionRayvolve (K240845)

Standalone specificity

0.8597 proportion

  • EndpointImage-level fracture detection
  • PopulationPediatric patients aged 2 years or older; all indicated study types and views, 3,016 radiographs
  • Tested versionRayvolve (K240845)

Standalone ROC-AUC

0.9399 ROC-AUC

  • EndpointImage-level fracture detection
  • PopulationPediatric patients aged 2 years or older; all indicated study types and views, 3,016 radiographs
  • Tested versionRayvolve (K240845)

Rayvolve pediatric standalone performance assessment

  • DesignStandalone performance assessment
  • PopulationPediatric patients aged 2 years or older across the indicated musculoskeletal study types and views
  • Scopeexact submission
  • Tested versionRayvolve (K240845)
  • Samplen=3016
  • IndependenceIndependence not established

K240845

The FDA packet states that no clinical study was conducted in support of K240845; this standalone assessment supported inclusion of the pediatric population.

Rayvolve regulatory performance study summary

  • DesignStand-alone performance and reader study (ACR AI Central category)
  • PopulationAdult and Pediatric
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K240845
  • Samplen=3016
  • IndependenceIndependence not established

K240845

Baseline ACR summary retained; FDA packet details above control endpoint and pediatric scope.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

No product-specific code

NICE HTG739 conditionally recommends Rayvolve for NHS use during a two-year evidence-generation period, subject to evidence-generation agreements and appropriate regulatory and DTAC approval; this is not a reimbursement determination.

NICE guidance for the NHS in England · England · Effective 2025-01-14

NICE's exploratory model uses GBP 1 per scan and says actual software, implementation, and postmarket costs are uncertain. This is not a vendor quote or US coverage evidence.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM radiographs from a DICOM Node or PACS, limited to the FDA-listed musculoskeletal study types and standard views: ankle, clavicle, elbow, forearm, hip, humerus, knee, pelvis, shoulder, tibia/fibula, wrist, hand, and foot.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K240845: Rayvolve

  2. Routing

    Source context, not route validation: The FDA packet describes current-edition DICOM interaction with existing DICOM Node servers such as PACS and clinical-grade viewers, with prediction output delivered as a processed DICOM image after the original.

    Scope: Exact FDA submission. Specific interface versions, routing, viewer behavior, and local compatibility remain acceptance-test items.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K240845: Rayvolve

  3. AI processing

    Source context, not route validation: On-premise or cloud platform connected to the radiology center local network and DICOM Node server.

    Scope: Exact FDA submission. The FDA summary does not establish current hosting region, retention, security controls, uptime, or commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K240845: Rayvolve

  4. Returned objects

    Source context, not route validation: Rayvolve outputs a prediction of potential fracture presence or absence and a processed image with bounding-box annotations localizing detected fractures; the initial image appears first and the processed image follows in the DICOM workflow, with annotations toggleable in the PACS/viewer.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K240845: Rayvolve

  5. Viewer/worklist/report

    Unresolved route: Rayvolve outputs a prediction of potential fracture presence or absence and a processed image with bounding-box annotations localizing detected fractures; the initial image appears first and the processed image follows in the DICOM workflow, with annotations toggleable in the PACS/viewer.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K240845: Rayvolve

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
On-premise or cloud platform connected to the radiology center local network and DICOM Node server.
  • Exact FDA submission
  • Checked 2026-09-07

The FDA summary does not establish current hosting region, retention, security controls, uptime, or commercial configuration.

Integration
The FDA packet describes current-edition DICOM interaction with existing DICOM Node servers such as PACS and clinical-grade viewers, with prediction output delivered as a processed DICOM image after the original.
  • Exact FDA submission
  • Checked 2026-09-07

Specific interface versions, routing, viewer behavior, and local compatibility remain acceptance-test items.

DICOM Node and PACS workflow

The exact FDA packet describes interaction with existing DICOM Node servers such as PACS and clinical-grade viewers, with the original image followed by the processed image containing fracture prediction and localization.

exact submission · checked 2026-09-07

Test representative identifiers, routing, image ordering, annotation toggles, and failure handling locally.

Deployment options

The FDA packet describes on-premise and cloud operation connected to the radiology center local network and DICOM Node server.

exact submission · checked 2026-09-07

Current hosting, PHI flow, retention, and service commitments are not established.

Current family workflow

AZmed's current Rayvolve page describes local PACS/workflow integration in a radiology customer testimonial and presents Rayvolve as an AI second opinion for fracture detection.

product family · checked 2026-09-07

Vendor page and testimonial; it does not establish a specific connector, PACS version, SLA, or local deployment result.

Independent assessment context

The NIHR/NICE early value assessment table describes Rayvolve in the assessed NHS context as using DICOM radiographs and integrating into existing hospital radiology workflows through Wellbeing's AI Connect gateway. That assessment lists Rayvolve as adult-only for its evaluated context, whereas the exact K240845 FDA indication includes pediatric patients aged 2 years or older.

product family · checked 2026-09-07

Historical assessment context; do not use it to narrow or expand the exact FDA indication without the K240845 packet.

Current NICE evidence-generation controls

NICE HTG739 conditionally recommends Rayvolve for use in NHS urgent care while evidence is generated and calls for local disagreement protocols plus monitoring of accuracy, software failures, downstream referrals, treatment changes, implementation cost, subgroups, and postmarket surveillance.

product family · checked 2026-09-08

English NHS health-technology guidance; not exact K240845 pricing, reimbursement, or US adoption evidence.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K240845
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
MSK
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07

Controlled anatomy normalization from the listed osteoarticular study types.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-07-17
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
29Fields reviewed
10Source classes checked
9Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

The stored evidence-candidates metadata and identifier lists were screened in order. This was metadata screening, not a full paper or ClinicalTrials.gov record review; no candidate abstract or full text is promoted here. The current discovery snapshot contains 9 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, health technology assessment, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission

    No current exact-product price or contract terms were established from the reviewed public sources. The NICE assessment used a notional cost input, not a vendor quote.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "AZmed Rayvolve reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-07 - Exact FDA submission

    The FDA comparison table contains a privacy characteristic, but the reviewed sources do not establish the current commercial security architecture, retention, access controls, audit, or incident-response terms.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-07 - Exact FDA submission

    The FDA packet says instructions for use are transmitted and used to train users; current onboarding, competency, and support commitments were not established.

  • Monitoring: Not verified - checked 2026-09-07 - Exact FDA submission

    Local acceptance testing, production monitoring, drift review, update control, and incident escalation remain to be qualified.

10 sources - 3 history items

Source ledger

  1. K240845 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Rayvolve model card (K240845)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: purpose, modality, intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. FDA 510(k) K240845: Rayvolve

    U.S. Food and Drug Administration - Published 2024-07-17 - Accessed 2026-09-07

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  8. Rayvolve AI Suite

    AZmed - Accessed 2026-09-08

    Scope: productFamily, clinicalWorkflow, PACS, implementationCapabilities

  9. NIHR/NICE early value assessment of AI fracture detection on X-rays

    National Institute for Health and Care Research / NICE - Accessed 2026-09-07

    Scope: productFamily, implementationContext, populationContext

  10. NICE HTG739: AI technologies to help detect fractures on X-rays in urgent care

    National Institute for Health and Care Excellence - Published 2025-01-14 - Accessed 2026-09-08

    Scope: conditionalAdoption, economics, evidenceGaps, implementationCapabilities

Research history

  1. K240845 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K242171

TechCare Trauma

Milvue

Authorized purpose: Aids clinicians and radiologists reviewing 2D X-ray radiographs by detecting, localizing, and characterizing fractures across the FDA-listed appendicular, hip/pelvis, clavicle, and thorax/rib examinations, and by detecting elbow joint effusion on lateral elbow or forearm views in children/adolescents and adults; results are not standalone clinical decisions.

Modality
X-ray/Radiography
Anatomy
MSK
Decision
2025-01-17
FDA-cleared K193417

FractureDetect (FX)

Imagen Technologies, Inc.

Authorized purpose: Assists clinicians in detecting fractures during review of adult musculoskeletal radiographs.

Modality
X-ray/Radiography
Anatomy
MSK
Decision
2020-07-30
FDA-cleared K251408

OsteoSight™ Hip (v1)

Naitive Technologies Ltd

Authorized purpose: Opportunistically analyzes standard AP hip or pelvis radiographs in patients aged 50 years and older and issues a report when the estimated femoral-neck BMD is below a preset threshold to prompt clinical bone-health assessment; absence of a report does not rule out low BMD.

Modality
X-ray/Radiography
Anatomy
MSK
Decision
2025-09-02
FDA-cleared K252953

Velmeni for Dentists (V4D) Endo-Perio

Velmeni, Inc.

Authorized purpose: Concurrent-read CADe to assist dentists in detecting specified tooth and jaw anatomy, bone-level landmarks, and root-canal-treated teeth in digital radiographs of permanent teeth in patients 15 years or older.

Modality
X-ray/Radiography
Anatomy
Permanent teeth and jaw/maxillofacial anatomy, including enamel, dentine, pulp, root, mental foramen, inferior alveolar canal, maxillary sinus, cementoenamel junction, crestal bone, and root-canal-treated teeth
Decision
2026-05-11

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history